These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 9636489)

  • 41. Role of protocol biopsies in the treatment of refractory renal allograft rejection with FK 506.
    Woodle ES; Thistlethwaite JR; Haas M; Josephson MA; Newell KA; Bruce DS; Millis JM; Piper JB; Charette JI
    Transplant Proc; 1996 Apr; 28(2):998-9. PubMed ID: 8623495
    [No Abstract]   [Full Text] [Related]  

  • 42. Is cyclosporine toxic to the transplanted kidney with acute tubular necrosis?
    Ritz M; Pascoe MD; Pontin AR; Kahn D
    Transplant Proc; 1998 Jun; 30(4):1204. PubMed ID: 9636488
    [No Abstract]   [Full Text] [Related]  

  • 43. Correlation of clinical outcomes after tacrolimus conversion for resistant kidney rejection or cyclosporine toxicity with pathologic staging by the Banff criteria.
    Morrissey PE; Gohh R; Shaffer D; Crosson A; Madras PN; Sahyoun AI; Monaco AP
    Transplantation; 1997 Mar; 63(6):845-8. PubMed ID: 9089224
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Posttransplant serum creatinine area under the curve predicts renal allograft outcome.
    Sumrani N; Hong J; Miles A; Markell M; Distant D; Fleishhacker J; Maursky V; Jean-Baptiste F; Sommer B
    Transplant Proc; 1996 Feb; 28(1):356-7. PubMed ID: 8644260
    [No Abstract]   [Full Text] [Related]  

  • 45. Intraoperative T-cell depletion prior to completion of anastomoses by high-dose single ATG bolus as a new approach to improve long-term results after kidney transplantation.
    Kaden J; May G; Strobelt V; Groth J; Müller P
    Transplant Proc; 1997; 29(1-2):344-7. PubMed ID: 9123032
    [No Abstract]   [Full Text] [Related]  

  • 46. Cyclosporine from twice to single daily dosing: impact on renal function, mortality, and graft loss.
    Bianco PD; Silva HT; Boni R; Machado PG; Pacheco-Silva A; Pestana JO
    Transplant Proc; 2002 Nov; 34(7):2920-1. PubMed ID: 12431657
    [No Abstract]   [Full Text] [Related]  

  • 47. Conversion from cyclosporine to tacrolimus in kidney, kidney/pancreas, and pancreas alone transplant recipients: the Memphis experience.
    Alloway RR; Russell WC; Gaber LW; Amiri MH; Vera SR; Gaber AO
    Transplant Proc; 1996 Apr; 28(2):995-7. PubMed ID: 8623494
    [No Abstract]   [Full Text] [Related]  

  • 48. Tacrolimus therapy for ABO-incompatible kidney transplantation.
    Takahashi K; Saito K; Sonda K; Nakagawa Y; Katagiri A; Tomita Y; Tanigawa T; Takeda M
    Transplant Proc; 1998 Jun; 30(4):1219-20. PubMed ID: 9636495
    [No Abstract]   [Full Text] [Related]  

  • 49. Predicting factors for long-term results of OKT3 therapy in steroid-resistant acute rejection following cadaveric renal transplantation.
    Rostaing L; Chabannier MH; Modesto A; Rouzaud A; Cisterne JM; Tkaczuk J; Durand D
    Transplant Proc; 1998 Jun; 30(4):1170-2. PubMed ID: 9636473
    [No Abstract]   [Full Text] [Related]  

  • 50. Kidney transplantation at extremes of age: CsA eliminates the increased risk in recipients < or = 5 or > or = 55 years.
    MacDonell RC; Van Buren DH; Richie RE; Johnson HK; Nylander WA; Helderman JH; Ynares CM; Trusler LA; Green WF; Crowe DA
    Transplant Proc; 1994 Oct; 26(5):2518-21. PubMed ID: 7940774
    [No Abstract]   [Full Text] [Related]  

  • 51. Conversion from conventional Sandimmun to Neoral therapy in stable renal transplant recipients.
    Løkkegaard H; Asmundsson P; Clausen P; Dieperink H; Hansen JM; Heaf J; Jensen SB; Kornerup HJ; Madsen S; Pedersen EB; Poulsen JV; Rasmussen K
    Transplant Proc; 1996 Aug; 28(4):2199-201. PubMed ID: 8769199
    [No Abstract]   [Full Text] [Related]  

  • 52. Long-term outcome of living-unrelated donor kidney transplantation.
    Prabhakar KS; Vathsala A; Woo KT
    Transplant Proc; 2000 Nov; 32(7):1807-8. PubMed ID: 11119945
    [No Abstract]   [Full Text] [Related]  

  • 53. Renal recipients of haploidentical living donors treated with Neoral or conventional cyclosporine: a comparative follow-up of 3 years.
    Gracida C; Melchor JL
    Transplant Proc; 1998 Aug; 30(5):1742-3. PubMed ID: 9723262
    [No Abstract]   [Full Text] [Related]  

  • 54. Tacrolimus/mycophenolate mofetil vs cyclosporine A/Azathioprine after simultaneous pancreas and kidney transplantation: five-year results of a randomized study.
    Woeste G; Wullstein C; Dette K; Pridöhl O; Lübke P; Bechstein WO
    Transplant Proc; 2002 Aug; 34(5):1920-1. PubMed ID: 12176629
    [No Abstract]   [Full Text] [Related]  

  • 55. Combined liver-kidney transplantation: long-term follow-up in 18 patients.
    Lang M; Kahl A; Bechstein WO; Neumann U; Settmacher U; Frei U; Neuhaus P
    Transplant Proc; 1998 Aug; 30(5):1865-7. PubMed ID: 9723313
    [No Abstract]   [Full Text] [Related]  

  • 56. Mycophenolate mofetil versus azathioprine in simultaneous pancreas-kidney transplant recipients on cyclosporine.
    Fabrega AJ; Corwin CL; Hunsicker L
    Transplant Proc; 1998 Jun; 30(4):1562-3. PubMed ID: 9636634
    [No Abstract]   [Full Text] [Related]  

  • 57. Cyclosporine therapy in pancreas transplantation.
    Davidson I; Lu C; Melone D; Risser R
    Transplant Proc; 1996 Aug; 28(4):2134-5. PubMed ID: 8769179
    [No Abstract]   [Full Text] [Related]  

  • 58. Low incidence of rejection after synchronous pancreas-kidney transplantation with Neoral.
    Cattral MS; Hemming AW; Greig PD; Rowsell C; Chari R; Wright E; Donat D; Cole E; Levy GA
    Transplant Proc; 1998 Aug; 30(5):1946. PubMed ID: 9723346
    [No Abstract]   [Full Text] [Related]  

  • 59. Mycophenolate mofetil eliminates the rationale for antilymphocyte induction therapy in nonhaploidentical living-donor kidney transplants.
    Shaffer D; Madras PN; Conway P; Davis C; Simpson MA; Monaco AP
    Transplant Proc; 1997; 29(1-2):342-3. PubMed ID: 9123031
    [No Abstract]   [Full Text] [Related]  

  • 60. Long-term experience with mycofenolate mofetil in the prevention of renal allograft rejection.
    Behrend M; Lueck R; Pichlmayr R
    Transplant Proc; 1997 Nov; 29(7):2927-9. PubMed ID: 9365617
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.